Background: Crizotinib is an ALK inhibitor and used for treatment in advanced stages lung adenocarcinoma patients with ALK (+). Most common side effects are; gastrointestinal disorder and visual side effects. Drugs are one of the reasons of effusion. For accurate diagnosis patients' drug history should be questioned in details. To the best of our knowledge pleural effusion due to crisotinib treatment does not exist in current literature. Method: 41 years old female patient's admitted to outpatient clinic with chest pain. There was a right hilar lesion and pleural effusion on right hemithorax ( Figure 1A ). Thorax tomography revealed 5 cm mass lesion in right middle lobe. Transthoracic needle aspiration biopsy reported as adenocarcinoma. Tissue was positive for ALK-rearrangement and first line crizotinib initiated. In the third month of treatment bilateral pleural effusion more in the right was occurred ( Figure 1B and 1C) . Primary lesion was regressed ( Figure  1D ). Efusion on left hemithorax was serous and exudate. Any malignant cells were observed. It was drained with pleural catheter and performed talk pleuredesis. There were lymphocytic cell predominance. Others reasons were excluded. Crizotinib treatment was interrupted, in 15 th day of crizotinib free observation fluid's amount decreased. To increase the rate of recovery methylprednisolone 40 mg/day is added. Result: Crizotinib started again with frequent clinical, radiological follow-up. Fluid's amount did not increase when steroid dose was tapered. While patient take 16 mg/day crizotinib, it has been seen that left pleural fluid disappeared and right pleural thickening appeared due to talc pleuredesis ( Figure 1E and 1F) . Conclusion: To the best our knowledge there is not case report with pleural effusion related to ALK TKI treatment. Our case is the first to demonstrate the relationship between ALK TKI treatment and pleural effusion. The case which response to the treatment newly formed pleural effusion's source may have thought as medication.
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Real-World Anaplastic Lymphoma Kinase Testing Practices: Results from a Survey in the United States K. Bloom, 1 S. Sudarsanam, 1 H. Hwang, 2 F. Racke, 3 S. Astrow, 4 M. Moran, 5 M. Chioda, 6 J. Sheng, 6 J. Ramage, 6 J. Mardekian, 6 A.J. Iafrate 7 1 Clarient Diagnostic Services, Inc., Aliso Viejo, CA/US, 2 Phenopath Pllc, Seattle, WA/US, 3 Quest Diagnostics Nichols Institute, San Juan Capistrano, CA/US, 4 Kite Pharma, Inc., Santa Monica, CA/US, 5 Cancer Genetics, Inc., Los Angeles, CA/US, 6 Pfizer Oncology, New York, NY/US, 7 Massachusetts General Hospital, Boston, MA/US Background: Anaplastic lymphoma kinase (ALK) translocation is a clinically validated predictive biomarker in multiple cancer types including non-small cell lung cancer, and widespread adoption of diagnostic assays permits a review of test performance. This analysis presents ALK and epidermal growth factor receptor (EGFR) testing rates, expediency, and results from 4 large national laboratories. Method: Deidentified data from January 2013 to December 2015 were compiled from 40 states and Washington DC and included in the final analysis. ALK status was evaluated with the Vysis ALK Break Apart FISH Probe Kit; EGFR status was evaluated by therascreen EGFR RGQ PCR Kit, cobas EGFR Mutation Test, or Sanger sequencing. Results from the most recent conclusive test were used. Collection to order (time from date of biopsy to date of biomarker test order), order to results (time from date of biomarker test order to date of available results), and overall turnaround times (collection to order + order to results) were evaluated. Results were analyzed by laboratories and US regions (Northeast, Midwest, South, and West) . Data were summarized with descriptive statistics. Result: s of 59,058 ALK and 50,992 EGFR tests were collected; 50,023 patients were tested for both ALK and EGFR, 9035 had results for ALK only, and 969 for EGFR only. Mean patient ages at ALK-positive (ALK + ) and EGFR-positive (EGFR + ) diagnoses were 62.5 and 69.0 years, respectively. Overall ALK + and inconclusive rates were 2.8% and 6.5%, respectively, vs 10.4% and 6.2% for EGFR testing. ALK + (2.3e5.1%) and inconclusive (1.1e17.4%) rates varied between test centers. In the western US, the ALK + rate (3.3%) was comparably greater than in other regions (2.4e2.7%). The median turnaround time was 15 days, with a median of 10 days for collection to order and 4 days for order to results; some regional variation was seen in turnaround time (14e18 days). No correlation was seen between age and turnaround time. Conclusion: EGFR + and ALK + rates and age distributions were consistent with prior reports. An interesting geographic difference in ALK rates was seen that warrants further investigation. The average turnaround time was longer than current guidelines recommend, suggesting an opportunity to improve current testing practices. Keywords: ALK-positive NSCLC, FISH, molecular diagnostic testing P3.13-04 Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer M. Paats, J. Minnema-Luiting, R. Cornelissen, J. Aerts Pulmonary Medicine, Erasmus MC, Rotterdam/NL Background: In this case series we present ten patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) treated with lorlatinib. Method: Lorlatinib is highly potent and selective third generation ALK and ROS1 tyrosine kinase inhibitor (TKI) with known activity against most resistance mutations. In a phase 1 study, lorlatinib showed intracranial and systemic activity in ROS1-positive and ALKpositive patients with advanced NSCLC. Result: Thus far, we treated 6 ALK-and 4 ROS1-positive stage IV NSCLC patients with lorlatinib in a compassionate use program. Best response was complete remission in two of our patients. One ROS1-positive patient with CNS metastases has now ongoing complete response for 27 months; the other patient with a ALK-positive NSCLC with CNS metastasis has now been treated with lorlatinib for 16 months. Three patients showed a partial response with an ongoing progression free survival of respectively 3, 5 and 8 months. Two of our patients (one ALK-positive and one ROS1-positive NSCLC) showed progressive disease as best response. In three patients response data is not (yet) available. There were no significant side effect apart from hypercholesterolemia, which occurred in four of our Background: The use of target therapy in lung cancer has changing the story of this disease. However, the toxicity sometimes can be a challenge. Method: We report a clinical case in a patient with advanced lung cancer with mutation in ROS 1 that had an excellent response with Crizotinib, but developed high levels of CPK. Result: Man, 75y, with an adenocarcinoma of the right lung with lesions in pleura. Tumor was assessed for EGFR mutation and ALK translocation, but were not found. We started chemotherapy with Carboplatin and Pemetrexed with partial response and, after four cycles, we continued treatment with Pemetrexed isolated. After thirteen cycles, he had bone progression and the chemotherapy was changed to Docetaxel. After that, he was submitted to three more lines of chemotherapy and immunotherapy with Nivolumabe. After four years of metastatic disease, a new bone progression with a sternal mass. new biopsy was made and found a mutation in the ROS 1 gene. He was very symptomatic, limited performance status (ecog 4) and was admmited in the hospital. We started treatment with Crizotinib 250 mg twice daily and he had a dramatic response. After two months, ECOG was one and a PET-CT showed almost a complete response. However, the patient started cramps in the abdomem and laboratory showed a CPK of 4500 u/l. the dose of the Crizotinib was adjusted to 250mg/day and the levels of cpk started to fall. We tried to reintroduce the full dose, but the levels of CPK increases to 4800 u/l again. So, we reduced the dose with maintenance of response and better tolerability. Conclusion: The increased levels of CPK with inibithors of alk is described with Alectinib. This relation with Crizotinib is not well estabilished. In this case, there was an excellent response, but the dose was limited by the increase of CPK. Background: Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs). Crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK rearrangement advanced NSCLC. The aim of this study is to investigate the clinical value of ALK rearrangement NSCLC blocks cell from pleural effusion. Method: Two hundred and fifteen cases of ALK rearrangement non-small cell lung cancer (NSCLC) blocks cell from pleural effusion, Four hundred and four cases of tissues were detected by reverse transcription polymerase chain reaction (RT-PCR) method. The consistency of ALK rearrangement was examined in 74 cases of patients with tissues and cell blocks. Result: ALK rearrangement was found in 26 of 215 cell blocks (positive detection rate of 12.09 %). ALK rearrangement was detected in 25 of 404 tissue blocks (positive detection rate of 6.19%). There were 67 cases in the 74 (90.54%) cases had the same consistency as tissue block. ALK rearrangement was detected in 11 of 74 (14.86%) cell blocks, and 14 of 74 (18.92%) tissue blocks. Conclusion: The rate of ALK rearrangement in cell blocks of NSCLC is higher than in matched tissue blocks. The patients with malignant pleural effusion are likely to tend ALK rearrangement. Keywords: non-small cell lung cancer, cell block, ALK P3.13-07 The Effect of Crizotinib in Patients of Non Small Cell Lung Cancer with Brain Metastases: A Retrospective Analysis
